Drugs to Treat Both Leber Congenital Amaurosis and Retinitis Pigmentosa Fast Tracked by FDA
September 15, 2011
QLT Inc. announced yesterday that the Company’s oral synthetic retinoid for retinal diseases, QLT091001, has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the treatment of Leber Congenital Amaurosis (LCA) due to inherited mutations in LRAT and RPE65 genes and for the treatment of autosomal recessive Retinitis Pigmentosa (RP) due to inherited mutations in LRAT and RPE65 genes.
The FDA’s Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended for the treatment of serious diseases and fill an unmet medical need.
Click here for the full release.
Jump down to form below to submit your own comments